2-硝基-4-叔丁基-6-溴苯胺 | 1027356-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-4-叔丁基-6-溴苯胺
• 英文名称: 2-bromo-4-tert-butyl-6-nitroaniline
• 英文别名: 2-bromo-4-tert-butyl-6-nitro-aniline；5-Brom-3-nitro-4-amino-1-tert.-butyl-benzol；2-Brom-4-tert-butyl-6-nitro-anilin；2-bromo-4-(1,1-dimethylethyl)-6-nitroaniline；2-Bromo-4-(tert-butyl)-6-nitroaniline
• CAS: 1027356-55-3
• 化学式: C₁₀H₁₃BrN₂O₂
• 分子量: 273.129
• InChiKey: HLULCDGWDGAVKY-UHFFFAOYSA-N

物化性质

• 熔点：
  61 °C
• 沸点：
  317.0±42.0 °C(Predicted)
• 密度：
  1.465±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2921420090

反应信息

• 作为反应物：
  描述：

  2-硝基-4-叔丁基-6-溴苯胺 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 sodium hydride 、 三乙胺 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 mineral oil 为溶剂， 反应 33.25h， 生成 1,1,1'-bis(tert-butoxycarbonyl)-4,4'-bis(triptycen-9-ylethynyl)-6,6'-di-tert-butyl-2,2'-bibenzimidazole
  参考文献：
  名称：

  Molecular Spur Gears Comprising Triptycene Rotators and Bibenzimidazole-Based Stators

  摘要：

  Dynamic gearing of molecular spur gears, the most common type of mechanical gear, is elucidated. Molecular design and conformational analysis show that derivatives of 4,4-bis(triptycen-9-ylethynyl)bibenzimidazole represent suitable constructs to investigate gearing behavior of collateral triptycene (Tp) groups. To test this design, DFT calculations (B97-D/Def2-TZVP) were employed and the results suggest that these molecules undergo geared rotation preferentially to gear slippage. Synthesis of derivatives was carried out, providing a series of molecular spur gears, including the first desymmetrized spur gear molecules, which were subsequently subjected to stereochemical analysis.

  DOI：

  10.1021/ja2063346
• 作为产物：
  描述：

  N-(4-叔丁基-2-硝基苯基)乙酰胺 在 溴 、 溶剂黄146 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.75h， 生成 2-硝基-4-叔丁基-6-溴苯胺
  参考文献：
  名称：

  Molecular Spur Gears Comprising Triptycene Rotators and Bibenzimidazole-Based Stators

  摘要：

  Dynamic gearing of molecular spur gears, the most common type of mechanical gear, is elucidated. Molecular design and conformational analysis show that derivatives of 4,4-bis(triptycen-9-ylethynyl)bibenzimidazole represent suitable constructs to investigate gearing behavior of collateral triptycene (Tp) groups. To test this design, DFT calculations (B97-D/Def2-TZVP) were employed and the results suggest that these molecules undergo geared rotation preferentially to gear slippage. Synthesis of derivatives was carried out, providing a series of molecular spur gears, including the first desymmetrized spur gear molecules, which were subsequently subjected to stereochemical analysis.

  DOI：

  10.1021/ja2063346

文献信息

• [EN] BENZIMIDAZOLE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE BENZIMIDAZOLE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011097491A1

  公开（公告）日：2011-08-11

  Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是公式(I)和(II)的化合物以及它们的药用可接受盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒（HCV）介导的病毒感染。
• [EN] ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF<br/>[FR] AGENTS ANTI-INFECTIEUX ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009039134A1

  公开（公告）日：2009-03-26

  This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这项发明涉及：(a) 抑制HCV等化合物及其盐；(b) 用于制备这种化合物和盐的中间体；(c) 包括这种化合物和盐的组合物；(d) 制备这种中间体、化合物、盐和组合物的方法；(e) 使用这种化合物、盐和组合物的方法；以及(f) 包括这种化合物、盐和组合物的试剂盒。
• [EN] URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C<br/>[FR] DÉRIVÉ D'URACILE OU DE THYMINE POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：ABBOTT LAB

  公开号：WO2009039127A1

  公开（公告）日：2009-03-26

  Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

  本申请涉及一种用于治疗丙型肝炎（HCV）感染的化合物，其化学式为I。所述化合物的结构中，尿嘧啶或胸腺嘧啶衍生物通过苯基与融合的2环环系统（R6）或者通过额外的两原子连接物（L）与5-6环单环（R6）相连。该申请还揭示了两种特定化合物的多晶形和伪多晶形：N-(6(3-叔丁基-5-(2>4-二氧化-3,4-二氢嘧啶-1(2H)-基)2-甲氧基苯基)萘-2-基)甲磺酰胺和(E)-N-(4(3-叔丁基-5-(2,4-二氧化-3,4-二氢嘧啶-1(2H)-基)2-甲氧基-苯乙烯基苯基)甲磺酰胺。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：de Vicente Fidalgo Javier

  公开号：US20100311760A1

  公开（公告）日：2010-12-09

  Compounds having the formula I wherein wherein R 1 , R 2 , R 3 , R 4 , X 1 , X 2 , X 3 and X 4 and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有化学式I的化合物，其中R1、R2、R3、R4、X1、X2、X3和X4如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了治疗HCV感染和抑制HCV复制的组合物和方法。
• ANTI-INFECTIVE AGENTS AND USES THEREOF
  申请人：Flentge Charles A.

  公开号：US20120244119A1

  公开（公告）日：2012-09-27

  This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  本发明涉及：(a) 包括抑制HCV的化合物及其盐；(b) 用于制备此类化合物和盐的中间体；(c) 包含此类化合物和盐的组合物；(d) 制备此类中间体、化合物、盐和组合物的方法；(e) 使用此类化合物、盐和组合物的方法；以及(f) 包含此类化合物、盐和组合物的试剂盒。